Automation and High-Throughput Technologies
Screening & Profiling at higher throughput using physiologically relevant cell models
Acute Myeloid Leukemia Drug Sensitivity Testing Using Patient-Derived Cells in 1536 Format
Lynn Rasmussen M.S.
Christopher Klug, Robert Bostwick, Miranda Burnette, AJ Reece
In practice the choice of which drug to prescribe for an individual patient is often made without any information on how that individual will respond to a specific drug. The field of precision medicine is attempting to provide data to fill that information gap in order to match the patient with the most effective treatment for that individual. To try to fill that gap for AML patients we have developed a drug screening process using a panel of FDA approved drugs with patient derived leukemia cells. Because the patient derived cells are an extremely limited resource, a 1536-well assay format was developed to maximize the amount of data that could be generated for each patient. The process of developing this assay will be discussed, including the technical challenges, their solutions and the equipment choices used to achieve a reliable HTS format screening protocol.